StreetAlpha.app
Home › Stocks › MYGN

Myriad Genetics Inc (MYGN)

Healthcare
$5.54
▼ −0.54%
LAST CLOSE · NOV 17

Myriad Genetics develops and sells molecular genetic tests for cancer, prenatal health, and mental health care. It last closed at $5.54 on Nov 17, down 0.54% on the day. The average 12-month price target from 6 analysts is $5.73 (+3.3% from the last close), with a high of $8.00 and a low of $2.00. Analyst consensus is Hold, based on the latest ratings from 6 firms (1 buy, 4 hold, 1 sell). In the past 30 days there were 1 dark pool print totaling $618K, the largest $618K.

AI Auto Pilots
Is MYGN in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$803.6M
−2.6% vs a year ago
Net income
−$129.1M
−16.1% margin
EPS (diluted)
−$1.35
Gross margin
68.3%
$549.1M gross profit
Valuation
Market cap
$531.4M
95.9M shares
P/E
–
No P/E while losing money
Price to sales
0.7
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$107.1M
At Sep 30
Debt
$121.1M
At Sep 30
Shareholder equity
$269.0M
Shares outstanding
95.9M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $690.6M$690.6MFY2021FY2022: $678.4M$678.4MFY2022FY2023: $753.2M$753.2MFY2023FY2024: $837.6M$837.6MFY2024FY2025: $824.5M$824.5MFY2025

From MYGN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 6). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Hold
Based on 6 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Hold
6firms
1 Buy4 Hold1 Sell
Each firm's latest rating on MYGN in the past 90 days
Average 12-month target
$5.73
▲ 3.3% upside

Based on 6 analysts who set a price target on MYGN in the past 90 days. The average target is $5.73, with a high of $8.00 and a low of $2.00, compared with the last close of $5.54.

Low $2.00Avg $5.73High $8.00
Blue marker: last close $5.54
Highest target$8.00
Average target$5.73
Lowest target$2.00
Latest rating changes
Stephens & Co.Target raised
Nov 12Hold$3 → $6
TD CowenTarget raised
Nov 5Hold$4.50 → $6.75
Leerink PartnersMaintained
Nov 5Hold$8
TD CowenTarget raised
Oct 13Hold$4 → $4.50
Craig-HallumMaintained
Oct 2Buy$8
DateFirmActionRatingPrice target
Nov 12Stephens & Co.Target raisedHold$3 → $6
Nov 5TD CowenTarget raisedHold$4.50 → $6.75
Nov 5Leerink PartnersMaintainedHold$8
Oct 13TD CowenTarget raisedHold$4 → $4.50
Oct 2Craig-HallumMaintainedBuy$8
Loading…

Technical Analysis

MYGN · as of the Nov 17 close · updated after every close
Uptrend

The stock sits between its 20 and 50 day averages. It is 17% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 51). The nearest support is the Pivot S1 at $5.40, and the nearest resistance the Pivot at $5.55.

Short trendBullish
Long trendBullish
MomentumFading
StretchNormal
VolatilityNormal, 6.2%/day
Key levels
$8.0952 week high+46.0%
$5.95Swing high (Oct 20)+7.4%
$5.9420 day average+7.2%
$5.69Pivot R1+2.7%
$5.55Pivot+0.2%
$5.54Last close
$5.40Pivot S1−2.5%
$4.8450 day average−12.6%
$4.61100 day average−16.8%
$4.61200 day average−16.8%
$4.19Swing low (Jun 15)−24.4%
$2.7452 week low−50.5%
Indicators
RSI (14)51.27Middle of its rangeNeutral
MACD0.22Below its signal lineBearish
Stochastic10.5Near the bottom of its rangeOversold
ADX (14)41.3Strong uptrend
Williams %R-90.8Oversold below −80, overbought above −20Oversold
CCI (20)-91.9Oversold below −100, overbought above 100Neutral
Rate of change−8.3%Change over 10 sessionsBearish
ATR (14)$0.34Typical daily range, 6.2% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Above
What happened before, for MYGN

What happened before

See how MYGN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow MYGN usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How MYGN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in MYGN in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$618K
Largest print
$618K
Loading…

MYGN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼83 buying vs 124 selling
  • ▼Held by funds -3.3 pts
  • ▼Funds holding -25
  • ▲Superinvestors: 4 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding176201−12.4%
In funds' top 1000–
Held by funds90.6%93.9%−3.3 pts
New / increased30 / 5346 / 75−31.4%
Reduced / sold out70 / 5458 / 46+19.2%
Put/call ratio0.350.07+431.5%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See MYGN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MYGN is in one of them and how their past MYGN trades turned out.

MYGN in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered MYGN in an article yet. Here's the latest on the wider market.

MYGN Congress Trades

All congress trades →
Trades, 12 months
1
Buys
0
0%
Sells
0
0%
People
1
Last filed May 14
Who traded MYGN · since 2026
Latest 1 filing
$15K – $50KTraded Mar 23, 2026Filed May 14, 2026
PersonTypeAmountTradedFiledDelay
Donald J TrumpExecutive branchOther$15K – $50KMar 23, 2026May 14, 202652 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Myriad Genetics

Myriad Genetics is a molecular diagnostics company based in Salt Lake City, Utah. It develops and sells genetic tests that help assess disease risk, guide cancer treatment, and support prenatal and mental health care. Its main areas are oncology, women's health, and mental health, with tests such as MyRisk for hereditary cancer risk and BRACAnalysis CDx for selecting cancer therapy. Its customers include doctors, healthcare providers, patients, and biopharma companies.

Headquarters
Salt Lake City, UT
Founded
1992